Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session on Genitourinary tumours

218MO - Comparison of a 22-gene genomic classifier (GC) with NCCN for risk stratification of Asian prostate cancers (PCa)


22 Nov 2020


Mini oral session on Genitourinary tumours


Woo Wai Yee


Annals of Oncology (2020) 31 (suppl_6): S1325-S1333. 10.1016/annonc/annonc369


W. Wai Yee1, A.Y.L. Sim2, K.P. Low2, A. Meng1, J. Tan1, J.K.L. Tuan1, T.W.K. Tan1, M.L.C. Wang1, L.S. Lee3, K. Tay3, C.W.S. Cheng3, C.S. Tan4, L.Y. Khor5, J. Yeong5, E. Davicioni6, M.L.K. Chua1

Author affiliations

  • 1 Division Of Radiation Oncology, NCCS - National Cancer Centre Singapore, 169610 - Singapore/SG
  • 2 Division Of Medical Sciences, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 3 Urology, Singapore General Hospital, 169610 - Singapore/SG
  • 4 Division Of Pathology, Changi General Hospital, 529889 - Singapore/SG
  • 5 Department Of Pathology, Singapore General Hospital, 169610 - Singapore/SG
  • 6 Decipher Biosciences, Inc., San Diego/US


Login to access the resources on OncologyPRO.

Abstract 218MO


Stratifying intermediate and high risk PCa is challenging due to the clinical heterogeneity of the disease. A 22-gene genomic classifier (GC) has demonstrated clinical utility in influencing treatment decisions in white and non-white men with PCa from Western cohorts. Here, we compared the GC with NCCN for risk stratification in an East-Asian PCa cohort.


GC (Decipher Biosciences, San Diego, CA) was performed on diagnostic biopsies or radical prostatectomy (RP) specimens in a pilot cohort (N=31). Gleason’s score (GS) and cellularity were reviewed by GU pathologist; RNA was extracted from 2 x 2.0-mm tumour cores using AllPrep DNA/RNA FFPE Kit and gene expression was performed on Affymetrix Decipher Biosciences array.


One (3.2%), 6 (19.4%), 9 (29.0%) and 10 (32.3%) were defined as NCCN low- (LR), intermediate- (IR), high- (HR) and very high-risk (VHR), respectively; 5 (16.1%) presented with M1 at diagnosis. The 22-gene GC classified one (3.2%), 7 (22.6%) and 23 (74.2%) as LR (<0.45), IR (0.45-0.6) and HR (>0.6), [hp2] [AS3] respectively. All M1 PCa patients harbored high GC scores (range 0.796-0.955). Of the 9 NCCN HR patients, 5 (55.6%) were downgraded to GC-IR; while the VHR patients were not affected. For the 6 NCCN IR patients, 4 (66.7%) in fact harbored high GC scores (0.6336-0.7458). Variance in GC scores was highest in GS 6-7 tumors (GC range: 0.3594-0.7458). Using the six-tier combined NCCN-GC risk grouping (Spratt et al.), 4 (66.7%) and 1 (16.7%) of 6 IR patients were reclassified as HR and LR, respectively. 4 (44.4%) of 9 HR who were GC-IR were classified as NCCN-CG HR, but 5 (55.6%) patients who were GC-HR were upgraded to NCCN-CG VHR. Lastly, transcriptome profiling by PAM50 signature revealed a higher proportion of basal than luminal subtypes in our East-Asian cohort (25 [80.6%] vs 6 [19.4%]) and a low proportion of ETS+/ERG+/SPINK1+ PCa (4 [12.9%]).


Here, we present our preliminary data suggesting the utility of GC in precise risk stratification of Asian PCa patients. A follow-up study is warranted to investigate the accuracy of the NCCN-GC risk grouping in predicting survival and influencing treatment decision making in Asian men with PCa.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


National Medical Research Council (NMRC), Decipher Biosciences (Structured research agreement).


E. Davicioni: Leadership role, Full/Part-time employment, Chief Scientific Officer: Decipher Biosciences. M.L.K. Chua: Research grant/Funding (institution): Decipher BioSciences. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings